Trial Profile
A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Subjects With Myelofibrosis (REFINE)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Jul 2023
Price :
$35
*
At a glance
- Drugs Navitoclax (Primary) ; Ruxolitinib (Primary)
- Indications Myelofibrosis; Polycythaemia vera
- Focus Therapeutic Use
- Acronyms REFINE
- Sponsors AbbVie; AbbVie Germany
- 13 Dec 2022 Results(As of Feb 07, 2022: N = 32 of Cohort-3) investigating whether the type of Myelofibrosis correlated with clinical outcomes and responses suggestive of disease modification among JAKi treatment naive patients and risk presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 10 Dec 2022 Results (n=32) published in an AbbVie media release.
- 10 Dec 2022 According to an AbbVie media release, exploratory analysis from Cohort 3 of the trial were presented in an oral presentation at the 64th American Society of Hematology Annual Meeting & Exposition (ASH).